Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
Madrigal Pharmaceuticals will present thirteen abstracts on Rezdiffra (resmetirom) at AASLD's The Liver Meeting 2026, held Nov. 5-9 in Denver. The data span its RESONANCE real-world evidence program, with the largest dataset covering more than 12,000 patients and examining effectiveness, tolerability, adherence and persistence in routine clinical practice.
Key figures
- Drug Name
- Rezdiffra (resmetirom)
- Phase Of Trial
- Phase 3 (MAESTRO-NASH)
- Rwe patient dataset
- more than 12,000 patients
- Vcte improvement or stabilization 100mg 1yr
- 91%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.